These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 16013932)

  • 1. [Therapeutic interchange standardization for antiotensin II receptor antagonists in the treatment of hypertension in the hospital setting].
    Porta Oltra B; Borrás Almenar C; Jiménez Torres NV
    Farm Hosp; 2005 Mar; 29(2):104-12. PubMed ID: 16013932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic interchange between angiotensin II receptor blockers in institutionalized elderly patients. Implimenting a protocol].
    Peris Martí JF; Faus Felipe VJ; de la Vega Ortega A; Martínez Romero G; Martínez Martínez MA
    Farm Hosp; 2003; 27(5):290-7. PubMed ID: 14576918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.
    Israili ZH
    J Hum Hypertens; 2000 Apr; 14 Suppl 1():S73-86. PubMed ID: 10854085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials.
    Stumpe KO
    Clin Ther; 2004; 26 Suppl A():A33-7. PubMed ID: 15291378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
    Smith DH; Dubiel R; Jones M
    Am J Cardiovasc Drugs; 2005; 5(1):41-50. PubMed ID: 15631537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data.
    Boersma C; Voors AA; Visser ST; de Jong-van den Berg LT; Postma MJ
    Am J Cardiovasc Drugs; 2010; 10(1):49-54. PubMed ID: 20104934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Newly emerging pharmacologic differences in angiotensin II receptor blockers.
    Oparil S
    Am J Hypertens; 2000 Jan; 13(1 Pt 2):18S-24S. PubMed ID: 10678284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic interchange of drugs not included in the hospitaĺs pharmacotherapeutic guide: a quality program].
    Navarro de Lara S; Font Noguera I; Lerma Gaude V; López Briz E; Martínez Pascual MJ; Poveda Andrés JL
    Farm Hosp; 2004; 28(4):266-74. PubMed ID: 15369437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Examining the association of olmesartan and other angiotensin receptor blockers with overall and cause-specific mortality.
    Lin JW; Chang CH; Caffrey JL; Wu LC; Lai MS
    Hypertension; 2014 May; 63(5):968-76. PubMed ID: 24516110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful implementation of a P&T-approved therapeutic interchange program of angiotensin II receptor blockers in a medical center in Taiwan.
    Lee YY; Hsiao P; Lin YM; Yen YH; Chen HY
    Value Health; 2012; 15(1 Suppl):S111-5. PubMed ID: 22265056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists.
    Michel MC; Foster C; Brunner HR; Liu L
    Pharmacol Rev; 2013 Apr; 65(2):809-48. PubMed ID: 23487168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switch strategies in the management of hypertension: a cost minimisation analysis of angiotensin receptor blocker based regimen.
    Belsey JD
    Curr Med Res Opin; 2008 Feb; 24(2):581-9. PubMed ID: 18198012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
    Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y
    Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis.
    Leclerc J; Blais C; Rochette L; Hamel D; Guénette L; Poirier P
    Circ Cardiovasc Qual Outcomes; 2017 Oct; 10(10):. PubMed ID: 28974512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Choice of angiotensin receptor blocker in moderate hypertension. A UK-based cost-benefit comparison of olmesartan- and candesartan-based regimens.
    Belsey JD
    J Med Econ; 2011; 14(5):553-61. PubMed ID: 21707445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palatability of angiotensin II antagonists among nephropathic children.
    Meier CM; Simonetti GD; Ghiglia S; Fossali E; Salice P; Limoni C; Bianchetti MG;
    Br J Clin Pharmacol; 2007 May; 63(5):628-31. PubMed ID: 17302913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of four angiotensin II receptor blockers in the treatment of hypertension.
    Miller LA; Wade R; Dai D; Cziraky MJ; Ramaswamy K; Panjabi S
    Curr Med Res Opin; 2010 Jun; 26(6):1307-20. PubMed ID: 20370377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker.
    Furuhashi M; Moniwa N; Mita T; Fuseya T; Ishimura S; Ohno K; Shibata S; Tanaka M; Watanabe Y; Akasaka H; Ohnishi H; Yoshida H; Takizawa H; Saitoh S; Ura N; Shimamoto K; Miura T
    Am J Hypertens; 2015 Jan; 28(1):15-21. PubMed ID: 24842388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experience with a two-tiered therapeutic interchange policy.
    Rich DS
    Am J Hosp Pharm; 1989 Sep; 46(9):1792-8. PubMed ID: 2572167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of angiotensin II receptor blocker on peritoneal membrane transports in continuous ambulatory peritoneal dialysis patients.
    Jearnsujitwimol V; Eiam-Ong S; Kanjanabuch T; Wathanavaha A; Pansin P
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S188-95. PubMed ID: 17044472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.